NEW YORK (GenomeWeb) – In deciding whether or not to cover noninvasive prenatal screening tests, payors place particular emphasis on evidence from clinical validation studies and recommendations from professional societies, according to a recent study.

In a study led by Andrew Dervan from the University of Washington that included collaborators from the American Institutes for Health Research, the University of California, San Francisco, and elsewhere, researchers analyzed publicly available coverage policies from 19 large US private payors regarding NIPS.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

A trial upgrade to 360Dx Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try 360Dx Premium now.

Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sep
20

This webinar will discuss how next-generation sequencing (NGS) can help clinical research labs and pathologists save time, money, and samples compared to single-analyte oncology research assays.

Sep
21

This webinar will demonstrate a new approach that combines precise FFPE tumor isolation with extraction-free DNA/RNA library preparation to minimize material losses and reduce the amount of tissue input required for NGS analysis.

Sep
27

This webinar will present an in-depth look at how Memorial Sloan Kettering Cancer Center has developed and implemented a next-generation sequencing panel for mutational tumor profiling of advanced cancer patients.

Sep
28

This webinar will discuss the critical role that software can play for clinical labs looking to establish comprehensive genomic testing programs.